Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates

Journal of Pharmaceutical Sciences

Volumn 100, Issue 12, 2011, Pages 5206-5218

  Wichitnithad, Wisut ^a   Nimmannit, Ubonthip ^a,b   Callery, Patrick S ^c   Rojsitthisak, Pornchai ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Biodegradable polymers; Conjugation; Curcumin; Cytotoxicity; PEGylation; Polymeric drugs; Prodrugs; Solubility; Stability

Indexed keywords

BUFFER; CARBOXYLIC ACID; CURCUMIN; ESTER; GLUTARIC ACID; MACROGOL 2000; METHYLCARBOXYLIC ACID; PRODRUG; SUCCINIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL STRAIN MCF 7; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; PLASMA; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 80054903598     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22716     Document Type: Article

References (61)

1. Administration USFDA. Substances generally recognized as safe. 1994. Essential oils, oleoresins (solvent-free) and natural extractives (including distillates).
2. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. 2005. A potential role of curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2:1-6.
3. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. 2008. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 76:1590-1611.
4. Abe Y, Hashimoto S, Horie T. 1999. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39:41-47.
5. Masuda T, Jitoe A. 1994. Antioxidative and anti-inflammatory compounds from tropical gingers: Isolation, structure determination, and activities of Cassumunins A, B, and C, new complex curcuminoids from Zingiber cassumunar. J Agric Food Chem 42:1850-1856.
6. Mishra S, Narain U, Mishra R, Misra K. 2005. Design, development and synthesis of mixed bioconjugates of piperic acid-glycine, curcumin-glycine/alanine and curcumin-glycine-piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 13:1477-1486.
7. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N. 2006. Curcumin (diferuloylmethane) inhibits constitutive active NF-κB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 118:765-772.
8. Hatcher H, Planalp R, Cho J, Torti FM, Torfi SV. 2008. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631-1652.
9. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. 2004. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854.
10. Sharma RA, Gescher AJ, Steward WP. 2005. Curcumin: The story so far. Eur J Cancer 41:1955-1968.
11. Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. 2008. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 1780:673-679.
12. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. 1997. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867-1876.
13. Joe B, Vijaykumar M, Lokesh BR. 2004. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 44:97-111.
14. Pan MH, Huang TM, Lin JK. 1998. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486-494.
15. Anand P, Kunnumakkara AB, Newman RB, Aggarwal BB. 2007. Bioavailability of curcumin: Problems and promises. Mol Phar 4:807-818.
16. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353-356.
17. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. 2007. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnol 5:3.
18. Li L, Braiteh FS, Kurzrock R. 2005. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322-1331.
19. Sahu A, Kasoju N, Bora U. 2008. Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 18(9):2905-2912.
20. Liu A, Lou H, Zhao L, Fan P. 2006. Validated LC/MS/MS assay for cucumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40:720-727.
21. Chaudhary H, Kohli K, Amin S, Rathee P, Kumar V. 2011. Optimization and formulation design of gels of diclofenac and curcumin for transdermal drug delivery by Box-Behnken statistical design. J Pharm Sci 100:580-593
22. Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK. 2005. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cycloxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 15:1793-1797.
23. Youssef D, Nichols CE, Cameron TS, Balzarini J, Clercq ED, Jha A. 2007. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 17:5624-5629.
24. Liang G, Yang S, Jiang L, Zhao Y, Shao L, Xiao J, Ye F, Li Y, Li X. 2008. Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin. Chem Pharm Bull 56:162-167.
25. Shim JS, Kim DH, Jung HJ, Kim JH, Lim D, Lee SK, Kim KW, Ahn JW, Yoo J S, Rho JR, Shin J, Kwon HJ. 2002. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem 10:2439-2444.
26. Qiu X, Liu Z, Shao WY, Liu X, Jing DP, Yu YJ, An LK, Huang SL, Bu XZ, Huang ZS, Gu LQ. 2008. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorg Med Chem 16:8035-8041.
27. Ferrari E, Lazzari S, Marverti G, Pignedoli F, Spagnolo F, Saladini M. 2009. Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. Bioorg Med Chem 17:3043-3052.
28. Harish G, Venkateshappa C, Rajeswara BM, Shiv KD, Krishna M, Neetu S, Shireen V, Srinivas Bharath MM. 2010. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. Bioorg Med Chem 18:2631-2638.
29. Dubey SK, Sharma AK, Narain U, Misra K, Pati U. 2008. Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties. Eur J Med Chem 43:1837-1846.
30. Parvathy KS, Negi PS, Srinivas P. 2010. Curcumin-amino acid conjugates: Synthesis, antioxidant and antimutagenic attributes. Food Chem 120:523-530.
31. Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM. 2004. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 39:123-133.
32. Lu J, Cheng C, Zhao X, Liu Q, Yang P, Wang Y, Luo G. 2010. PEG-scutellarin prodrugs: Synthesis, water solubility and protective effect on cerebral ischemia/reperfusion injury. Eur J Med Chem 45:1731-1738.
33. Manju S, Sreenivasan K. 2011. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci 100:504-511.
34. Elvira C, Gallardo A, Roman JS, Cifuentes A. 2005. Covalent polymer-drug conjugates. Molecules 10:114-125.
35. Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, Schiavon O, Summerford C, Tirk A, Veronese FM, Vincenzi V, Wu G. 2005. Poly (ethylene glycol)-poly (ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates. Biomacromolecules 6: 914-926
36. Pashankar DS, Loening-Baucke V, Bishop WP. 2003. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediat Adolesc Med 157:661-664.
37. Wali RK, Kunte DP, Koetsier JL, Bissonnette M, Roy HK. 2008. Polyethylene glycol mediated colorectal cancer chemoprevention: Roles of epidermal growth factor receptor and snail. Mol Cancer Ther 7:3103-3111.
38. Calceti P, Salmaso S, Walker G, Bernkop-Schnürch A. 2004. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur J Pharm Sci 22:315-323.
39. Safavy A, Raisch KP, Mantena S, Sanford LL, Sham SW, Krishna NR, Bonner JA. 2007. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem 50:6284-6288.
40. Li J, Wang Y, Yang C, Wang P, Oelschlager DK, Zheng Y, Tian D, Grizzle WE, Buchsbaum DJ, Wan M. 2009. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 76:81-90.
41. Greenwald RB, Pendri A, Bolikal D. 1995. Highly water soluble taxol derivatives: 7 Polyethylene glycol carbamates and carbonates. J Org Chem 60:331-336.
42. Greenwald RB, Choe YH, McGuire J, Conover CD. 2003. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55:217-250.
43. Pabon HYY. 1964. A synthesis of curcumin and related compounds. Rec Trav Chim 83:379-386.
44. Buadonpri W, Wichitnithad W, Rojsitthisak P, Towiwat P. 2009. Synthetic curcumin inhibits carrageenan-induced paw edema in rats. J Health Res 23:11-16.
45. Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. 2002. Improved HPLC method for the determination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. J Agric Food Chem 50:3668-3672.
46. Wichitnithad W, Jongaroonngamsang N, Pummangura S, Rojsitthisak P. 2009. A simple isocratic HPLC method for the simultaneous determination of curcuminoids in commercial turmeric extracts. Phytochem Anal 20:314-319.
47. Williams FM, Asad SI, Lessol MH, Rawlins MD. 1987. Plasma esterase activity in patients with aspirin-sensitive asthma or urticaria. Eur J Clin Pharmacol 33:387-390.
48. Plumb JA, Milroy R, Kaye SB. 1989. Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49:4435-4440.
49. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421-5426.
50. Priyadarsini KI. 2009. Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J Photo Chem Rev 10:81-95.
51. Roughley PJ, Whiting DA. 1973. Experiments in the biosynthesis of curcumin. J Chem Soc Perkin Trans I 20:2379-2388.
52. 13C NMR studies of selected vinylogues of dibenzoylmethane (curcumine analogues). Pharmazie 53:28-32.
53. Payton F, Sandusky P, Alworxsxth WL. 2007. NMR study of the solution structure of curcumin. J Nat Prod 70:143-146.
54. Montaudo G, Montaudo M, Puglisi C, Samperi F. 1995. Characterization of polymers by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: Molecular weight estimates in samples of varying polydispersity. Rapid Commun Mass Spectrom 9:453-460.
55. Wetzel SJ, Guttman CM, Girard JE. 2004. The influence of matrix and laser energy on the molecular mass distribution of synthetic polymers obtained by MALDI-TOF-MS. Int J Mass Spectrom 238:215-225.
56. Wetzel SJ, Guttman CM, Flynn KM, Filliben JJ. 2006. Significant parameters in the optimization of MALDI-TOF-MS for synthetic polymers. J Am Soc Mass Spectrom 17:246-252.
57. Davaran S, Rashidi MR, Hanaee J, Hamidi AA, Hashemi M. 2006. Synthesis and hydrolytic behavior of ibuprofen prodrugs and PEGylated derivatives. Drug Delivery 13:383-387.
58. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. 2005. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-84.
59. Williams FM, Nicholson EN, Woolhouse NW, Adjepon-Yamoah KK, Rawlins MD. 1986. Activity of esterases in plasma from Ghanaian and British subjects. Eur J Clin Pharmacol 31:485-489.
60. Mishra S, Webster P, Davis ME. 2004. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83:97-111.
61. Guerra-Tschuschke I, Martin I, Gonzalez MT. 1991. Polyethylene glycol-induced internalization of bacteria into fungal protoplasts: Electron microscopic study and optimization of experimental conditions. Appl Environ Microbiol 57:1516-1522.